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A new strategy for the skin delivery of bioactive compounds has been developed, using enzymes involved in the
maintenance of the epidermal barrier function and the enzymatic transformation of corresponding precursors. This
new strategy has been tested with regard to two enzymatic activities of the skin barrier: extracellular glucosidase
and esterase/lipase. An analysis of the requirements for the glycosidic bond hydrolysis of any glycoconjugate by b-
glucocerebrosidase indicates that the release of the moiety linked to the glucose unit is obtained as long as the
glycosidic bond being broken is not hindered, and as long as the leaving group property of the released moiety is
good enough. This strategy was ﬁrst applied to the release of the antioxidant d-tocopherol. It was then extended to
retinoic acid by introducing a spacer between the glucose unit and the bioactive moiety. This spacer was either a
good leaving group such as hydroquinone, or a structure akin to a ceramide, namely glycerol. In these conditions,
b-glucocerebrosidase releases the complex spacer-active compound that is cleaved by an esterase. One of the
advantages of this strategy lies in the slow release of the bioactive compound, extending in time its effect and most
likely its tolerance, as is the case for retinoic acid.
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In recent years, a better understanding has been gained
concerning skin barrier formation, particularly with regard to
the progressive maturation of keratinocytes from the basal
layer of the epidermis, but also with regard to the formation
of the lipid matrix, where the keratinocytes are embedded
(Holleran et al, 1991; Elias, 1996). These processes are
controlled by a number of enzymes (Redoule`s et al, 1998),
among them b-glucocerebrosidase, which transforms
glycosylceramides into ceramides (Holleran et al, 1993),
and phospholipases, which transform phospholipid precur-
sors into free fatty acids (Mao-Qiang et al, 1995). Other
enzymes contributing to skin processing and to barrier
function homeostasis are sphingomyelinases, sulfatases,
esterases (Menon et al, 1986; Zettersten et al, 1998), tryptic,
and chymotryptic enzymes, and cathepsin-D, these latter
three being involved in the desquamation process (Suzuki
et al, 1994; Horikoshi et al, 1999).
The strategy developed in this work was to consider that
part of this enzymatic activity could be used as a drug de-
livery route; indeed, several approaches have been devel-
oped for overcoming the skin barrier for molecular
transport, yet none of them appears fully satisfying (Naik
et al, 2000). These are transdermal drug delivery system,
microemulsions, liposomal systems, additives such as al-
cohols, fatty acids, polar solvents, peptides, and proteins
(Prausnitz et al, 2004). But such improvements are modest,
and owing to the lability of penetration enhancers, frequent
administrations are required, thus increasing the skin dam-
age that most of them provoke. Physical enhancement
technologies also suffer from practical limitations. For ex-
ample, iontophoresis, in which a small electrical current is
applied on the skin (Guy, 1992), and electroporation (high-
voltage short-duration pulses) (Prausnitz, 1995) cannot eas-
ily be used. Therefore, the alternative of taking advantage of
the skin’s enzymatic activity seemed justified to us. Sur-
prisingly, this alternative has not yet been considered.
The development of this strategy requires that the cor-
responding enzymes are not too specific toward pseudo-
substrates, and that the target enzyme or enzymes can be
reached from the skin surface.
We chose b-glucocerebrosidase for the following rea-
sons:
(i) It accumulates in the superficial part of the skin as shown
from the tape-stripping results (Tarroux et al, 2002). Here
it is largely responsible for the formation of epidermal
lipids (Elias and Menon, 1991). It is present outside the
cells in the stratum corneum and in the lysosomal com-
partment of living cells (Qi and Grabowski, 1998).
(ii) It appears to be of low specificity, since it is assayed
using 4-methylumbelliferyl-b-D-glucopyranoside, a com-
pound very different in structure from b-D-glucosylcer-
amide, the normal substrate of b-glucocerebrosidase.
(iii) It has an affinity for amphiphilic molecules such as
bromoconduritol b-epoxide, which freely diffuses in the
stratum corneum, since bromoconduritol b-epoxide
Abbreviations: K13, keratin 13; RHE, reconstituted human
epidermis
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
270
inhibits b-glucocerebrosidase when it is applied topi-
cally (Holleran et al, 1992).
In this work, we demonstrate that pseudosubstrates of b-
glucocerebrosidase, bearing compounds of physiological
interest such as tocopherol, undergo transdermal delivery,
and are efficiently hydrolyzed by the enzyme. This delivery
process provides additional benefits, such as stabilization
of the active compound and continuous reinforcement of
natural skin antioxidants by the slow release of the additive.
This strategy can then be extended to any kind of com-
pound by the use of a spacer introduced between the glu-
cose unit and the additive. This particularly holds true for
retinoic acid, a major compound used in dermatology, be-
cause of the fact that its glycoconjugate is not cleaved by b-
glucocerebrosidase, as far as we could observe. A spacer
such as hydroquinone, or glycerol, a structure akin to the
natural ceramide structure, overcomes this limitation. The
use of either spacer requires the action of a second en-
zyme, an esterase, also present in the epidermis (Tran et al,
2001). This second step may equally be a result of lipase
action (Harrison, 2000; van Bennekum et al, 2000; Maury
et al, 2002).
Accordingly, the kinetics of retinoic acid release was as-
sessed from arbutin retinoate on a human epidermis model,
and the advantages of the strategy in terms of biological
activity and tolerance were checked.
Results
Kinetic constants (KM and Vm) of glycoconjugate hy-
drolysis by recombinant b-glucocerebrosidase After we
observed that the enzyme extracted from corneocytes was
of too small an amount to be able to measure the extent of
hydrolysis of the pseudosubstrates, compounds 1–6 (Table
I) were assayed with recombinant b-glucocerebrosidase.
In a first step, the enzyme was assayed using the ref-
erence substrate 4-methyl-umbellyferyl-glucopyranoside
with determination of the KM and Vm parameters (see Ta-
ble I). pH dependence was examined between 4.5 and 7.5
pH values, showing an optimum at 5.5. At pH 7.5, the ac-
tivity is only 25% of that at 5.5. Hydrolyses were run in
sealed flasks at 371C. Trials at 501C showed that hydrolysis
was reduced to 5% of the value at 371C after the same
period, because of enzyme thermal denaturation. Finally,
runs in the presence of the inhibitor bromo-conduritol
epoxide at 0.1 mM concentration showed full hydrolysis
blocking.
Concerning other compounds in Table I, the results were
as follows: hydrolysis with good efficacy was observed un-
der three conditions:
(i) For compounds with a low pK, hydrolysis was observed
for compound 3 (pK¼ 8.45). It was lower for compound 2
(pK¼ 10), and was not observed for compound 4
(pK¼ 16).
(ii) For compounds with a strong hydrophobic moiety that
are recognized with a high affinity by the enzyme, hy-
drolysis was observed. For example, a comparison of
the kinetic parameters for reference substrate 1 and for
compound 5 shows that the hydrophobic part of 5 is
responsible for increased affinity by three orders of
magnitude, whereas the hydrolysis rate is decreased by
a factor of only 20, resulting in increased Vm/KM.
(iii) In the absence of a steric hindrance in the vicinity of the
broken bond, hydrolysis was observed as is shown by
comparing the results obtained with compounds 5 and
6 (Table I).
As the release of retinoic acid from a glycosyl conjugate
was not possible as we observed, we introduced a spacer
between the glucose and retinoic acid moiety. This spacer
was removed following the action of an esterase since it is
linked to the bioactive molecule through an ester group.
Two spacers were used: a hydroquinone unit with a good
leaving group effect (compound 7, Table I) and glycerol, a
structure bearing some similarities to a ceramide structure,
with two possible configurations (compounds 8 and 9). The
first phase, hydrolysis by b-glucocerebrosidase, indicates
that compounds 7, 8, and 9 are recognized and hydrolyzed.
Compound 7 has higher efficiency, confirming the impor-
tance of the leaving group effect. Indeed, the corresponding
values of hydrolysis rates for compounds 7, 8, and 9 are
235, 74, and 17, respectively, for similar KM values. In ad-
dition, for compounds 8 and 9, with a glycerol unit as a
spacer, it was observed that the stereochemistry at the sn-2
position of glycerol had no effect on the affinity for the en-
zyme (KM), but the R form was hydrolyzed four times faster
than the S form (Vm).
Kinetics of metabolism of compound 7 (arbutin retino-
ate) on reconstituted human epidermis (RHE) The de-
livery of free retinoic acid from compound 7, a good
substrate for glucocerebrosidase, was studied on recon-
structed human epidermis. The skin metabolism of the pro-
drug was determined at 3, 18, 42, and 72 h. Table II shows
hydrolysis of the starting material and formation of hydro-
quinone retinoate under the action of b-glucocerebrosidase.
After 3 h, 16.5 nmol of hydroquinone retinoate were col-
lected in the RHE (and underlying medium), which repre-
sented about 23% of the starting material. This amount of
hydroquinone retinoate was found as remaining fairly con-
stant with time over the 3 d, suggesting a possible reservoir
effect. Table II shows the kinetics of released retinoic acid
under an esterase activity at the four intervals tested. It can
be seen that the concentration of retinoic acid remains low
and increases slightly to reach 1.8 nmol at 42 h and 3.7
nmol at 72 h, which represents an extent of transformation
of compound 7 of 2.5% and 5%, respectively. This indicates
a high metabolism of retinoic acid or/and a weak esterase
activity.
In situ hydrolysis of glycoconjugate 5 After we checked
that the hydrolysis of glycoconjugate 5 by b-glucocerebro-
sidase occurs, we determined that this hydrolysis occurs
in natural conditions. Twelve volunteers were treated with
compound 5 applied topically to the forearm twice a day for
14 d. Table III shows the corresponding results. Free d-to-
copherol was observed in the treated area only. It was ob-
served that glycoconjugate 5 was only partially hydrolyzed 1
d after the last application, since 1.32  1010 mol per cm2
of glycoconjugate was measured in the epidermis, com-
pared with 0.149  1010 mol per cm2 of free d-tocopherol.
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The same results were observed after 5 d of treatment, ev-
idence that the proportion of the two molecules reached an
equilibrium. This confirms that after a few days, a precursor
remains in the skin and produces d-tocopherol. Thus, a
reservoir effect can be obtained.
Natural a-tocopherol, also identified in the assay, re-
mained at the same level in both the treated and untreated
areas. The amount of d-tocopherol was approximately three
times that of a-tocopherol. The glycoconjugate of a-tocop-
herol, which bears 2-methyl substituents a to the phenyl
group, was not hydrolyzed by glucocerebrosidase and
therefore this ruled out using it. It is known, however, that
the antioxidant efficiency of the d form is equivalent to or
higher than that of the a form (Bourgeois, 1981).
Relative biological activity of glycoconjugate 7 versus
active compound Human epidermis reconstituted in a de-
fined medium enables detailed detection of the specific ef-
fects of active retinoids on basal cell proliferation and of the
graduated epidermal differentiation process. Application of
an excipient containing 6.6 nmol retinoic acid (0.025%)
onto the mature stratum corneum of air-raised cultures pro-
voked the appearance of keratins (K13, K19), typical of a
hyperproliferative epidermis, and inhibited the synthesis of
Table I. Kinetic constants (KM and Vm) of glycoconjugates hydrolyzed by recombinant b-glucocerebrosidase
Structure of
glycoconjugate Molecule released KM (per mM)
Vm (nmol per h
per mg)
Vm/KM (per h
per mg per 103)
1
OOH
HO OH
HO
O OO
4-methylumbelliferyl-glucopyranoside
1
4-methylumbelliferone 7.2  0.8 9300  650 1.3
2
OOH
HO OH
HO
O
2
Phenol 430 mM Not accessible
3
OOH
HO OH
HO
O
O
O
3
4-hydroxy-methyl benzoate
19.8  4.9 1983  363
0.1
4
OOH
HO OH
HO
O
4
Benzyl 0
5
OOH
HO OH
HO
O
O ] 3[
5
d-tocopherol 7  1  103
453  20
65
6
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O ]3[
6
g-tocopherol 0
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profilaggrin in the granulous layer (Rosdy et al, 1997). Figure
1 shows the results obtained with compound 7 compared
with those of the retinoic acid, and compared with those of
the excipient alone. The excipient does not change the
pattern of expression of marker proteins (data not shown).
Concerning the markers K13, K19, and profilaggrin, the re-
sults of compound 7 show a level comparable with that
observed with retinoic acid as a positive control, i.e. an ex-
pression of K13 and K19 and an inhibition of profilaggrin.
Relative tolerance of glycoconjugate 7 versus active
compound Within the context of this study, the cutaneous
irritation potential of compound 7 was determined after
topical application of 7.2 nmol of compound 7 on RHE for
72 h. Accordingly, the release of inflammatory mediators IL-
8 (De Brugerolle de Fraissinette et al, 1999) in the medium
underneath the tissues was quantified using the ELISA
method. Table IV shows the results obtained in a quadru-
plicate run in vitro over 72 h. It can be observed that com-
pound 7 induces a slight increase of IL-8 release compared
with that of the excipient only, whereas 6.6 nmol of retinoic
acid per assay (at the usual 0.025% concentration) in the
same excipient induces a greater increase in IL-8. After
three applications of retinoic acid, the inflammatory marker
IL-8 showed a significant increase, and reached 179 pg per
mL, whereas the repeated topical application of compound
7 did not markedly affect its level (72 pg per mL).
Discussion
Many drugs exhibit undesirable properties affecting their
stability, absorption, metabolism, or tolerance. A drug may
be unstable, as is the case for tocopherols, or it may not
Table II. Hydrolysis of arbutin retinoate 7 on reconstructed human epidermis (unit: nmol per 4 cm2 of assay surface)
0 3 h 18 h 42 h 72 h
Arbutin retinoate 72 25  3.6 14  0.5 6.5  1.5 3.1  0.4
Hydroquinone retinoate 0 16.5  3.8 19  0.5 21.3  1.5 16.8  1
Retinoic acid 0 0.1  0.03 0.2  0.07 1.8  0.04 3.7  0.3
Total arbutin retinoate, hydroquinone retinoate, and retinoic acid found in the reconstituted human epidermis (RHE) (mediumþ epidermis) at 3, 18, 42,
and 72 h (mean  SE).
Table I. Continued
Structure of
glycoconjugate Molecule released KM (per mM)
Vm (nmol per h
per mg)
Vm/KM (per h
per mg per 103)
7
O
O
O
HO
OH
HO
OH
O
7
Arbutin retinoate
5  1.2
235  19 47
8
O
HO
OH
HO
OH
O
O
O
O
O
R
8
Di-retinoyl glycerol
8.6  2.5
74  7 8.6
9
S
O
O
O
O
O
O
HO
OH
HO
OH
9
Di-retinoyl glycerol
5  0.4
17  0.4 3.4
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possess the right balance between lipid solubility and water
solubility for its absorption in the skin. In addition, a drug
can be metabolized too easily to be effective, or it can be
too irritant, as a consequence of its local accumulation, as
is the case for retinoic acid.
Our approach in overcoming such undesirable properties
is to use skin enzymes to release slowly active compounds
from corresponding prodrugs. In our work, we have shown
that b-glucocerebrosidase is able to recognize and hydro-
lyze pseudosubstrates that are very different in structure
from the natural glucosylceramide; moreover, b-glucocer-
ebrosidase reveals itself to be suitable for drug delivery,
since it is active from the very first layers of the skin, as
shown from the tape-stripping results. The limiting factors
for the cleavage of any glycoconjugate are the pK value of
the leaving group (compounds 2–4), the leaving group lip-
ophilic contribution (compounds 2 and 5), and the steric
hindrance in the a position of the glycosidic bond (com-
pounds 5 and 6). Furthermore, hydrolysis of pseudosubst-
rates by glucocerebrosidase is less efficient if we compare
the kinetic values estimated for compound 5 (Vm/KM¼0.065
per hper mg per protein) to those of the natural substrate
2R, 3R glucosylcerebroside (Vm/KM¼21 per h per mg per
protein) (Sarmientos et al, 1986). This relatively low efficien-
cy allows a reservoir effect of the precursor and a slow
release of the active compound. This could be evaluated as
we showed in another body of work (Mavon et al, 2004): the
part of the free metabolite tocopherol formed from precur-
sor 5 was determined in viable human skin and found to be
time dependent as follows: 5% was present after 2 h incu-
bation, 12% after 6 h, and 19% after 18 h.
In addition, the glucose moiety allows the photos-
tabilization of the tocopherol compound1 which, in normal
conditions, is quickly degraded by light, and provides an
amphiphilic character to compensate for the low penetra-
tion of tocopherol through lipid membranes. Indeed, in
Table IV. Release of inﬂammatory mediator IL-8
IL-8 (pg per mL) (n¼4)
Single
application
Repeated applications
(three times in all)
Negative control 16.9  8.9 34.4  6.6
Arbutin retinoate
(7.2 nmol)
37.3  11.6 72.3  20.7
Retinoic acid
(6.6 nmol)
67.7  13.1 179.4  73.6
Reconstituted human epidermis (RHE) models were treated topically
for 3 d with compound 7. IL-8 concentration was estimated in the un-
derlying medium.
Table III. Clinical studies of in situ hydrolysis of glycoconju-
gate 5 (unit: 1011 mol per cm2 of assay surface)
Treated area Control area
d-tocopheryl-glucopyranoside (5) 12.5  10 0
d-tocopherol 1.4  7.3 0
a-tocopherol 0.57  0.38 0.52  0.27
Tocopherol and tocopherol glucoside concentrations after 14 d of
treatment by compound 5 at 0.1% concentration in an excipient, versus
the control area treated by the excipient only. This comparative blind
study was carried out on the forearms of 12 volunteers; the side to which
the product was applied was determined for each subject by random
draw. The treatment was applied twice daily: once in the evening after
washing and once the following morning.
Figure 1
Detection of retinoic acid activity by topical application on reconstituted human epidermis. Appearance of markers K-13 and K-19 and
disappearance of filaggrin (epidermal-specific differentiation markers) of keratinized epithelium treated 3 d with excipient only, with arbutin retinoate,
and with retinoic acid. Keratin K13, keratin K19, and filaggrin were revealed by immunohistological technique. Nuclei were stained with propidium
iodide. Scale bars 40 mm.
1Pierre Fabre Patent: WO9946273, compositions containing a
compound that liberates active material on contact with cutaneous
glucocerebrosidase.
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contrast to the free drug, the polar glucoconjugation pro-
vides an improvement in the protective activity against both
matrix metalloproteinase expression and genomic DNA al-
teration, as shown on human skin fibroblasts stressed un-
der the action of phorbol 12-myristate 13-acetate and TNFa,
respectively.2 In this case, the use of an amphiphilic prodrug
could increase the extent of parent drug delivery into
the cells by the lysosomal b-glucocerebrosidase (Qi and
Grabowski, 1998).
This approach is also of value for local treatment with
drugs causing side effects such as skin irritation, since the
prodrug accumulates at the site of action and releases the
active compound slowly over a long period of time. Re-
tinoids have been successfully used in several dermatoses,
e.g. congenital disorders of keratinization, acne, photoag-
ing, psoriasis, epithelial precancers, and tumors, lichen
planus, etc. (Zouboulis and Orfanos, 2000). Because re-
tinoic acid is applied daily for treatment of skin disorders, it
can be assumed that substantial amounts of free retinoic
acid will accumulate at the site of application after several
days, producing local irritation and other side effects (Lucek
and Colburn, 1985). Consequently, we have developed re-
tinoic acid delivering glycoconjugates, in which two kinds of
spacers between the glucose unit and the retinoic acid
moiety are used. We found that prodrug 7 with a good
leaving group effect because of the spacer is hydrolyzed by
b-glucocerebrosidase at a suitable rate, inducing a reservoir
effect; moreover, the spacer that connects the bioactive
moiety to the glucose unit controls the rate of enzymatic
hydrolysis, adding extra flexibility to the systems. The re-
lease of retinoic acid from prodrug 7 and its corresponding
effects were determined in an RHE model. We observed
that the arbutin-type prodrug 7 was hydrolyzed, first by b-
glucocerebrosidase, and then by esterase. In these condi-
tions, free retinoic acid derived from the topical application
of compound 7, insofar as we could determine, did not ac-
cumulate in the skin. The topical application of compound 7
on the RHE model resulted in the retention of biological
activity of retinoic acid and induced less irritation. Therefore,
compound 7 might serve as a retinoid reservoir that delivers
controlled amounts of retinoic acid to receptor-binding
sites, and consequently helps prevent toxic effects.
Based on these observations, the examples presented
above show that this drug delivery route through skin en-
zymes is open to development, and should be exploited for
diverse purposes in the near future.
Materials and Methods
Reagents Chemicals and buffers were purchased from Sigma (St
Louis, Missouri). Solvents (HPLC grade) and buffers were filtered
with 0.45 mm nylon membranes (Pall Gelman Laboratory, Ann
Arbor, Michigan). The adhesive used for stripping was a 3M prod-
uct (reference 3M FR 850, 3M, St. Paul, Minnesota). b-glucor-
ebrosidase was expressed in baculovirus-infected cells and
purified to 80% by affinity chromatography. The 4 cm2 RHE was
supplied by Skinethic Laboratories (Nice, France). The RHE, a
three-dimensional multilayered epidermis, was obtained by grow-
ing the keratinocytes for 17 d on the surface of a defined medium
(Rosdy et al, 1997) in a CO2 incubator (5% CO2, 371C). In these
conditions, the RHE can be maintained viable for several days.
Synthesis of the glycoconjugate compounds The glycoconju-
gate compounds were prepared by the method described by Sch-
midt (1986). Briefly, after specific deprotection at carbon 1 of
glucopyranose protected in the acetylated form, the reaction with
trichloroacetonitrile in the presence of sodium hydride in dichloro-
methane led to the imidate a isomer only. The corresponding imi-
date was then reacted with the alcohol unit in the b-configuration
under Lewis acid catalysis leading to the prodrug in the b config-
uration only. Finally, acetyl groups were deprotected using an ion
exchange resin (Amberlist A-26) at room temperature. The prod-
ucts were purified by means of column chromatography. The cor-
responding analytical data for compounds 2–6 are inserted as
supplementary material.
Arbutin retinoate 7 was synthesized by coupling retinoic acid
with arbutin (2 eq.) in the presence of N-(3-dimethylamino propyl)-
N0-ethylcarbodiimide (1 eq.) and 4-(dimethylamino)-pyridine (0.25
eq.) at 01C in freshly distilled CH2Cl2 and DMF. The reaction was
maintained for 3 h under argon at 251C, and the product was then
filtered and purified by HPLC. The synthesis of compounds 8 and 9
has been published previously (Redoule`s and Pe´rie´, 1999). De-
tailed purification procedures and structural features have been
described elsewhere3 for compounds 7–9.
Determination of the rate constants (KM and Vm) of the in vitro
hydrolysis of glycoconjugates by recombinant b-glucocereb-
rosidase The protein concentration of b-glucocerebrosidase was
determined by absorbance measurement at 280 nm. A standard
quantity of b-glucocerebrosidase was added to a 3 mL flask con-
taining aqueous phthalate buffer (25 mM, pH 5.6) including sodium
taurocholate (5 mM). The substrate was tested at various concen-
trations. The flasks were sealed and gently stirred at 371C for 1 h.
They were then placed in cryogel chilled to 201C. The reaction
medium was neutralized by the addition of a 0.5 mL Tris buffer (pH
7, 0.2 M) kept at 41C. After vigorous shaking, the aglycone part was
extracted with 1 mL of ethyl acetate. The hydrolysis product was
almost completely extracted after a single liquid–liquid extraction,
except for the phenolic derivatives, which were assayed after two
successive extractions. An aliquot of the organic fraction (0.6 mL)
was then evaporated and taken up in 0.3 mL of methanol. For each
of the substrates studied, the quantity of product released was
determined in triplicate. A control sample without added b-
glucocerebrosidase was processed in the same conditions. The
kinetic constants KM and Vm were calculated from the data ob-
tained after adjustment of the curves to the Michaelis–Menten
equation by non-linear regression.
The amount of 4-methylumbelliferone released was directly as-
sayed with a Hitachi spectrofluorimeter (excitation¼ 360 nm/emis-
sion¼ 450 nm) on 50 mL of the organic phase added to 1 mL of 0.2
M sodium bicarbonate buffer pH 10.5.
Tocopherols, phenolic compounds, and retinoic derivatives
were assayed by high-performance liquid chromatography. The
system used included a Hewlett Packard series 1100 isocratic
pumping setup with an automatic injector, a fluorimetric detector,
and a variable wavelength detector (Agilent Technologies, Palo
Alto, California).
Following separation on a high-density Nucleosil C18 125
mm  4 mm, 5-mm column, the tocopherols were assayed by flu-
orimetric detection (Ex¼ 280 nm, Em¼ 350 nm). The mobile phase
was methanol–water 95:5 (v/v) at a flow rate of 1 mL per min. The
retinoic derivatives were assayed in the same column with UV de-
tection at 350 nm. The column was eluted with methanol:water
2Haure MJ, Baudouin C, Arie`s MF, et al: Delta-tocopheryl glu-
copyranoside (tocopherol precursor) in the skin: An anti-oxidant
that protects the extracellular matrix. J Invest Dermatol 122:A35,
2004 (abstr).
3Pierre Fabre Patent: WO200058325, bioprecursors of retinoic
acids well tolerated on topical application, useful for treating pso-
riasis and ichthyosis, for depigmentation and to counter skin aging.
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(95:5, v/v) for 4-hydroxy–phenol retinoate and pure methanol for
1,2-diretinoyl glycerol. The phenolic derivatives were assayed on a
C18 ODS3 250 mm  4.6 mm, 5-mm column with fluorimetric de-
tection (excitation¼ 270 nm/emission¼ 310 nm). The mobile phase
was methanol–water (65:35, v/v) at 1 mL per min.
Kinetics of metabolism of arbutin retinoate (compound 7) on
RHE The experiment was conducted with a finite dose of 20 mL (5
mL per cm2) containing 72 nmol of arbutin retinoate gently depos-
ited onto the RHE. Two RHE samples were analyzed per test time,
and each experiment was performed in duplicate. The RHE was
cut into small pieces and transferred into a 15 mL glass tube con-
taining 3 mL of propan-2-ol and dichloromethane 2:1 v:v. This
same phase was used for extraction in the medium (3 mL phase/1
mL medium). Each vial was shaken vigorously for 10 min. The
extract was directly injected into the HPLC for analysis.
The HPLC system consisted of a Hewlett Packard Model 1100
diode array detector (detection at lmax: 338 nm for all-trans retinoic
acid, 367 nm for arbutin retinoate and hydroquinone retinoate, 350
nm for retinoid compounds). The products were eluted using an
XTERRA RP18 column, 5 mm, 250 mm  4.6 mm (Waters Corpo-
ration, Milford, Massachusetts) and a gradient mobile phase con-
sisting of the eluent A: methanol/ammonium acetate 10 mM in
water (3:1 vol:vol), and eluent B: methanol/dichloromethane (4:1
vol:vol), at a flow rate of 0.8 mL per min. The eluent was 100% A
from 0 to 0.5 min; then there was a gradient of the mixture from A
to B up to 14 min; then the eluent was 100% B from 14 to 22 min.
Finally, there was a gradient from B back to A, up to 25 min.
In situ hydrolysis of glycoconjugate 5 This study was conduct-
ed according to the Declaration of Helsinki Principles and was
approved by the French Ethical Committee (CCPPRB) in Toulouse,
France. Volunteers were enrolled in the study after giving their
written informed consent.
A preparation of 0.1% d-tocopheryl-glucopyranoside in an ex-
cipient (o/w emulsion) was applied to the forearms of 12 female
volunteers (3.52 nmol per cm2). The excipient alone was applied to
the other forearm, which served as a control. Application was re-
peated twice a day for 14 d. Samples were taken 1 d after the last
application on treated and untreated skin regions. The superficial
layer of the stratum corneum was removed by three successive
strippings, and then d-tocopheryl-glucopyranoside and its me-
tabolite d-tocopherol were extracted by applying 4 mL ethyl ac-
etate in a glass cylinder (13 cm2). This was repeated once to
extract more than 90% of the accessible compounds. Both ethyl
acetate extracts were pooled, concentrated under nitrogen, and
taken up in 400 mL of methanol before being assayed by HPLC.
Biological activity of glycoconjugates The biological activity
was assessed using immunohistology studies. Tests were carried
out by Skinethic Laboratories. Briefly, 8 mL of each test product
(o/w emulsion with a gel aqueous phase, containing 0.05% w/w
arbutin retinoate and 0.025% w/w retinoic acid in the same ex-
cipient) was deposited onto the surface of the stratum corneum of
four RHE models, using a micropipette. After topical application of
the test products for 72 h, 4 mm vertical sections were fixed in 10%
formalin and embedded in paraffin and then reacted with specific
antibodies and peroxidase-conjugated antibodies according to
standard protocols. Monoclonal anti-K19, anti-K13, and anti-filag-
grin antibodies were from NeoMarkers (Fremont, California) (Rosdy
et al, 1997).
Tolerance of glycoconjugates Tolerance was estimated by re-
cording the release of inflammatory mediators. The RHE models
were treated as in biological activity studies. The test product was
applied by a micropipette onto the surface of the stratum corneum
of the RHE models, once on day 17 and again on days 17, 18, and
19. Seventy-two hours after the first application of the test prod-
ucts (day 20), conditioned media underneath the epidermal cul-
tures were collected in quadruplicate and kept frozen at 201C for
IL-8 inflammatory mediator quantification, using the ELISA kit (R&D
Systems, Abington, UK, Catalogue Number D8000C, batch
number 219254). Results are expressed in pg mediator released
per mL of conditioned medium.
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